Detalles de la búsqueda
1.
Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-438547
2.
One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-438218
3.
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-957472
4.
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-305441
5.
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-222232
6.
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516125
7.
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-475303
8.
Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-514592
9.
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-462234
10.
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430500
11.
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430866
12.
Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-308965
13.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-234674
14.
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-233536
15.
Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-512216
16.
Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-459480
17.
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-451222
18.
A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-470767
19.
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-437942
20.
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-201616